

# Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer

Claudia M. Dollins,<sup>1,2</sup> Smita Nair,<sup>2</sup> David Boczkowski,<sup>2</sup> Jaewoo Lee,<sup>2</sup> Juliana M. Layzer,<sup>2</sup> Eli Gilboa,<sup>3</sup> and Bruce A. Sullenger<sup>1,2,\*</sup>

<sup>1</sup>University Program in Genetics and Genomics

<sup>2</sup>Duke Translational Research Institute and Department of Surgery

Duke University Medical Center, Durham, NC 27710, USA

<sup>3</sup>Department of Microbiology and Immunology, School of Medicine, University of Miami, Miami, FL 33136, USA

\*Correspondence: [bruce.sullenger@duke.edu](mailto:bruce.sullenger@duke.edu)

DOI 10.1016/j.chembiol.2008.05.016

## SUMMARY

We show that a molecular scaffold can be utilized to convert a receptor binding aptamer into a receptor agonist. Many receptors (including tumor necrosis receptor family members) are activated when they are multimerized on the cell surface. Molecular scaffolds have been utilized to assemble multiple receptor binding peptide ligands to generate activators of such receptors. We demonstrate that an RNA aptamer that recognizes OX40, a member of the tumor necrosis factor receptor superfamily, can be converted into a receptor-activating aptamer by assembling two copies on an oligonucleotide-based scaffold. The OX40 receptor-activating aptamer is able to induce nuclear localization of nuclear factor- $\kappa$ B, cytokine production, and cell proliferation, as well as enhance the potency of dendritic cell-based tumor vaccines when systemically delivered to mice.

## INTRODUCTION

RNA ligands or aptamers that bind protein targets can be isolated from a combinatorial library of RNA sequences through the SELEX process (Ellington and Szostak, 1990; Tuerk and Gold, 1990; Fitzwater and Polisky, 1996). Aptamers are an emerging class of therapeutic agents that are potentially useful in a wide variety of therapeutic settings, including tumor immunotherapy (Nimjee et al., 2005; Santulli-Marotto et al., 2003). RNA aptamers offer several advantages over traditionally used therapeutic agents, including the ability to inhibit protein-protein interactions (Burmeister et al., 2005), an avoidance of immunogenicity (Macugen, 2007), and the opportunity to rapidly reverse the aptamer's activity via an "antidote" oligonucleotide (Rusconi et al., 2002; Dyke et al., 2006; Nimjee et al., 2006). Here we sought to determine if a molecule scaffold could be employed to convert a receptor binding aptamer into a receptor agonist, targeting the cell surface receptor OX40.

The modulation of receptor signaling during immune responses has tremendous potential for the treatment of a wide range of diseases, including inflammation, autoim-

mune disease, heart disease, and cancer. In particular, the development of therapeutic agents that can modulate the function of the tumor necrosis factor (TNF) receptor superfamily has received much attention. Because these receptors are activated by ligand-induced multimerization on the cell surface, the development of multimeric receptor binding ligands has been a particular focus. For example, Fournel et al. (2005) recently demonstrated that a molecular scaffold could be decorated with peptide ligands that recognize the TNF receptor family member CD40, and this multivalent ligand could activate CD40 receptor function. Here we evaluate whether such a scaffold approach can be employed to convert an aptamer that recognizes the OX40 receptor into a receptor agonist.

OX40 (CD134, TNFRSF4) is also member of the TNF family of receptors. OX40 is expressed on the surface of activated T cells, and interaction with its ligand, OX40 ligand, leads to increased immune function manifested by T cell proliferation and cytokine production (Weinberg, 2002; Sugamura et al., 2004; Watts, 2005). As with many other receptors involved in modulating immune cell function (e.g., CD28, CD40, 4-1BB) (Melero et al., 2007), agonistic antibodies targeting OX40 have been developed (al-Shamkhani et al., 1996). In vitro and in vivo studies have demonstrated that such antibodies can enhance tumor immune responses by inducing dimerization of the OX40 receptor on the cell surface. The promise of the monoclonal antibody preclinical data led to a phase I clinical trial with OX40 agonistic antibodies as potential cancer therapeutics (Weinberg et al., 2006). Unfortunately, the murine origin of the antibody used in this trial generated concern about the possibility of antimurine immune responses following a single administration. Thus, in the only clinical trial that has been reported, the safety and efficacy of OX40 antibody treatment could not be established through multiple administrations (Morris et al., 2007). More recently, a trimeric OX40 ligand fused to the human IgG Fc has been developed as an alternative OX40 agonist for use in patients, but its in vitro and in vivo functionality remains to be determined (Morris et al., 2007). As an alternative to such protein-based agents, we sought to determine if RNA aptamers could be utilized to stimulate murine OX40 function. Here we describe how a malleable oligonucleotide-based molecular scaffold can be employed to convert an RNA aptamer against murine OX40 into a receptor-activating aptamer.

## RESULTS

### Isolation of OX40 Aptamers and Identification of Aptamer Sequences

RNA aptamers specific to the T cell costimulatory receptor OX40 were isolated by the SELEX method (Ellington and Szostak, 1990; Tuerk and Gold, 1990; Fitzwater and Polisky, 1996). Murine OX40 human IgG Fc fusion protein was coupled to protein G-coated beads to facilitate RNA partitioning. To avoid amplification of RNA binding undesired portions of this construct, RNA capable of interacting with the human IgG Fc or protein G alone were removed from the randomized RNA library via preincubation with these proteins. This “precleared” RNA pool was then added to the immobilized murine OX40 fusion protein. The OX40 binding RNA was reverse transcribed and amplified by RT-PCR, and a secondary enriched RNA library was created by *in vitro* transcription. This “selection round” was repeated 10 times with enhancing stringency, defined as increasing RNA:protein ratios. Selection progress was monitored by comparing binding affinities of the SELEX round RNA to the protein after each round of selection (Figure 1A). After binding affinity no longer increased following additional selection rounds, the sequences of the isolated aptamers were determined.

As shown in Figure 1B, this process yielded a number of RNA aptamers that bound OX40 with varying affinities ( $K_D = 8\text{--}625$  nM). Aptamer 9.8 was chosen for further study, since it had the highest affinity for the OX40 fusion protein. To ensure that RNA aptamer 9.8 bound OX40 and not the Fc portion of IgG or protein G that were used in the selection, we performed additional binding studies. Such analysis demonstrates that aptamer 9.8 binds the extracellular domain of murine OX40 (see Figure S1 in the Supplemental Data available online).

To control for nonspecific activity, we created a mutant aptamer containing two point mutations (aptamer 9.8PM; Figure 1B) that disrupt the aptamer-OX40 interaction. To generate the mutant aptamer, we utilized the RNA structure prediction algorithm m-fold (Zuker, 2003). The lowest resulting free-energy structure is depicted in Figure S2. We chose to mutate two nucleotides in a conserved loop of the aptamer. These nucleotide substitutions maintain the overall predicted structure of the aptamer, but abolish its ability to bind OX40 (Figure 2D). This mutant aptamer served as a control in all of our cell and *in vivo* studies.


### Converting the OX40 Aptamer into a Receptor-Activating Aptamer

Unfortunately, the monomeric aptamer 9.8 is unable to stimulate OX40 function (Figure S3). In an attempt to convey OX40 agonistic activity to aptamer 9.8, we considered characteristics of known OX40 agonists. Agonists known to functionally activate the OX40 receptor include antibody formulations (al-Shamkhani et al., 1996) and multimerized versions (dimerized/trimerized [Morris et al., 2007]) of OX40s natural ligand (OX40 Ligand) (Figure 2A). These proteins share the common feature of possessing multiple binding sites for OX40. They have the capacity to crosslink receptor subunits, leading to receptor activation and signaling. Therefore, we developed a DNA scaffold that is able to bind two copies of the aptamer 9.8 (Figure 2B). DNA was chosen for the scaffold as we wanted to avoid double-stranded RNA

(dsRNA), to address concerns about Toll-like receptor activation due to the fact that dsRNAs have been shown to bind and activate cell surface-expressed Toll-like receptors (Kleinman et al., 2008). The aptamer annealing sites on the scaffold were separated by a polyethylene spacer. This spacer was chosen to provide flexibility to the assembled complex, as a model of the structure of OX40 complexed with the OX40 ligand indicated that the receptors in the natural receptor-ligand complex are positioned between 39 and 76 Å apart from one another. Incubation of aptamer 9.8 with the DNA scaffold at a ratio of 2:1 resulted in three different species: a DNA scaffold with two bound aptamers, a scaffold with a single bound aptamer, and unbound aptamer. The three different species were purified via native PAGE followed by elution (Figure 2C). When two copies of the aptamer are assembled on the DNA scaffold, they retain their ability to bind the murine OX40 with high affinity (Figure 2D). Furthermore, the aptamer dimers were shown to be capable of binding to two OX40 molecules by gel shift analysis (Figure S4).

OX40 activation is known to serve as costimulatory signal and enhance T cell proliferation (Ali et al., 2004), induce cytokine secretion (Kawamata et al., 1998), and initiate T cell signaling events (Aggarwal, 2003). We next sought to determine if the fully assembled DNA scaffold-dimeric aptamer complex could elicit these effects. We primed murine T cells with the antigen *Staphylococcal enterotoxin B* (SEB) *in vivo* (Figure 3A), and mice were sacrificed and their lymph nodes removed. Single-cell suspensions of the lymph node-derived cells were labeled with carboxy fluorescein succinimidyl ester (CFSE), as outlined in the Experimental Procedures (Ali et al., 2004). The fluorescently labeled cells were restimulated with the SEB antigen *in vitro* in the presence of the OX40 bivalent aptamer-DNA scaffold. As shown in Figure 3B and Figure S5, treatment of the cells with SEB in addition to either the scaffold-assembled bivalent aptamer or an agonistic OX40 antibody (OX86) led to an increase in cell proliferation. By contrast, the mutant aptamer containing scaffold and an isotype control antibody had no effect. Thus, a DNA scaffold can be utilized to assemble two copies of aptamer 9.8 in close proximity to one another and convert the OX40 aptamer into a receptor-activating aptamer.

Activation of the OX40 receptor also results in the induction of interferon (IFN)- $\gamma$  secretion (Aggarwal, 2003; Kawamata et al., 1998). Therefore, to confirm our cell proliferation results, we evaluated the levels of IFN- $\gamma$  secreted from receptor-activating aptamer-treated lymph node cells. As shown in Figure 3C, addition of the DNA scaffold-aptamer dimer resulted in a dramatic increase in the production of this cytokine. By contrast, the aptamer-scaffold complex did not induce TNF- $\alpha$  expression, indicating that the Toll-like receptors were not being stimulated by the aptamer treatment (Figure S6). Finally, since activation of OX40 is known to result in the increased nuclear translocation of nuclear factor (NF)- $\kappa$ B (Aggarwal, 2003; Arch and Thompson, 1998), we isolated and evaluated the nuclear fractions from cells for NF- $\kappa$ B following treatment with the aptamer-DNA scaffold complex (Mi et al., 2006). As shown in Figure 3D, treatment with either the aptamer-DNA complex or an agonistic OX40 antibody resulted in NF- $\kappa$ B nuclear localization. By contrast, treatment with the mutant aptamer-containing complex had no effect on NF- $\kappa$ B localization. Collectively, these results indicate that, when two copies of aptamer 9.8 are dimerized by a DNA



**Figure 1. Isolated OX40 Aptamers and Binding to Recombinant and Cell Surface OX40**

(A) The binding affinities for the indicated SELEX rounds to a murine OX40-IgG Fc fusion protein were determined by differential filter binding (RNA pool [black squares], round 3 [dark gray squares], round 5 [medium gray squares], round 7 [light gray squares], round 9 [lightest gray squares], and round 11 [white squares]).

(B) Summary of aptamer sequences against murine OX40, including a point mutant version of aptamer 9.8 (9.8 PM) and their binding affinities. The sequence of the 5' (GGGAGGACGATGCGG) and 3' fixed regions (CAGACGACTCGCTGAGG ATCCGAGA) have been excluded for brevity.

potency of a DC tumor vaccine in vivo (DC-TRP-2 + control aptamer versus DC-TRP-2 + OX40 aptamer;  $p \leq 0.05$ ).

## DISCUSSION

Through the use of the TNF receptor family member OX40 as an example, our results demonstrate that RNA aptamers dimerized through annealing to a molecular scaffold can act as receptor agonists.

RNA aptamers represent a class of molecules with inherent advantages over the use of antibodies as therapeutic agonists. In contrast to many protein-based therapeutic agents, aptamers can be safely administered repeatedly without eliciting compound-specific antibodies (Macugen, 2007). The OX40 agonistic antibody currently in clinical development was developed in a murine host; therefore, its administration is limited to a single dose, because of the potential to develop human anti-mouse antibodies as a reaction to the protein of murine origin (Morris et al., 2007). This shortcoming is particularly limiting for treatment of chronic diseases, such as cancer. Moreover, the potential exists for patients to develop neutralizing antibodies to humanized monoclonal antibodies following repeated administration.

Recently, we described an example of an aptamer agonist (McNamara et al., 2007). However, the approach taken to generate this aptamer agonist is restrictive. Two aptamers were cross-linked through the addition of two complementary sequence extensions to form an aptamer dimer. Each stretch of 21 RNA nucleotides formed a base-paired linker that is approximately 65 Å in length and is fairly rigid (Figure S7A). This method of aptamer crosslinking is limiting due to the difficulty in varying crosslinker length and the restriction to the number (Talmage et al., 1977) of conformations the crosslinked molecule can adopt. If the paired section is too short, stability is compromised, while further increases in aptamer length greatly decrease aptamer yields through in vitro transcription or chemical synthesis. Moreover the length of the complex is critical for the formation of an aptamer agonist, as the goal is to crosslink multiple receptor monomers to induce signaling.


In a paper by Santulli-Marotto et al. (2003), multimerization of two CTLA-4 dimers through aptamers that were arrayed on

scaffold, the complex is able to activate the OX40 receptor on primed T cells in culture.

### OX40 Receptor-Activating Aptamer Function In Vivo

To determine if the OX40 receptor-activating aptamer can also act as an agonist in vivo, we evaluated the compound's ability to induce OX40 function in a tumor immunotherapy setting. More precisely, we assessed its ability to enhance anti-tumor responses generated by dendritic cells (DCs) transfected with a tumor antigen (Nair and Boczkowski, 2002). DCs are antigen-presenting cells that can be modified to present antigens to activate T cells. One approach to supplying antigens to DCs is through messenger RNA (mRNA) transfection. Vaccination with antigen-pulsed DCs has been previously shown to induce tumor immune responses. To evaluate the OX40 receptor-activating aptamer's activity in vivo, we evaluated its ability to enhance a DC-based antitumor vaccine in mice.

Female C57/BL6 mice were implanted with B16-F10.9 melanoma tumor cells and vaccinated with DCs pulsed with either the melanoma antigen tyrosinase-related protein 2 (TRP-2) or actin (control) mRNA (Figure 4A). The vaccine was systemically administered in the presence of OX40 receptor-activating aptamer, mutant OX40 aptamer, OX40 agonistic antibody, or an isotype control antibody (Nair et al., 2007). As shown in Figure 4B, administration of DCs containing the TRP-2 antigen alone delayed the development of a palpable tumor compared to control antigen-treated animals, but did not lead to a cure with all animals developing tumors by Weeks 25–30. However, administration of either the OX40 receptor-activating aptamer or the OX40 agonistic antibody to animals receiving the DC-TRP-2 vaccination resulted in tumor-free survival in 30%–40% of the animals for over 40 days. Thus, systemic administration of the OX40-activating aptamer significantly enhanced the



### Figure 2. Aptamer Dimerization Approach

(A) Threading-based structural model of murine OX40L bound to murine OX40. Shown is a cartoon of a trimeric murine OX40L complex (gray ribbon with transparent surface) liganded with murine OX40 (blue) (PDB code: 2HEY). Each OX40L protomer is liganded stoichiometrically 1:1 to OX40. The shortest (39.1 Å) and longest (75.8 Å) inter-OX40 distances to equivalent residues are denoted by the red dashed line.

(B) Aptamer 9.8 or point mutant were dimerized by annealing to an oligonucleotide (green) containing two sites for aptamer hybridization separated by a polyethylene spacer.

(C) Dimerization of RNA aptamers through the use of a DNA scaffold. RNA aptamers were dimerized by heat annealing to a DNA scaffold at a 1:1 ratio of binding sites. The resulting mixture of dimer (two aptamer + scaffold) and monomer (one aptamer + scaffold) were PAGE-purified with an 8% native polyacrylamide gel. The identity of gel-eluted dimers was verified by rerunning the dimerized RNA on a PAGE gel and visualization using ethidium bromide. The image colors have been inverted for ease of viewing.

(D) Aptamer dimers retain binding affinity to purified OX40 protein. Gel-purified aptamer dimers were radioactively labeled, and their binding affinities to murine OX40-IgG Fc fusion protein were determined by differential filter binding. Shown are binding curves of OX40-Fc fusion protein to aptamer monomer (squares), aptamer dimer (triangles), point mutant monomer (inverted triangles), or point mutant dimer (diamonds) ( $n = 3$ ). Error bars indicate  $\pm 1$  SEM.


a complementary scaffold was used as a means to increase avidity, as illustrated in Figure S7B. However, the mode of dimerization in this case does not alter the functionality of the aptamers, as it is not designed to affect the dimerization of individual CTLA-4 receptors, but merely increase the apparent binding affinity through increased valency.

This study is the first demonstration of using a scaffold to arrange two aptamers to crosslink receptor monomers and thereby induce receptor function. The scaffold approach is based on a duplex formation allowing for more flexibility, as the scaffold contains a polyethylene glycol linker (Figure S7C) that conveys flexibility much like the hinge region in an antibody (Figure S7D). This approach could allow for application to many other cell surface receptors, as the scaffold can accommodate a variety of distances and conformations much like molecular calipers (Figure S7C). Furthermore, the scaffold-based approach taken in this study has the advantage of being amenable to optimization. For example, to enhance the activity of this particular agonistic aptamer, a variety of modifications to the scaffold could be explored: The length of the spacer that is currently

18 carbons in length could be varied to enhance this particular aptamers' ability to crosslink two OX40 receptor monomers and induce signaling. Moreover, the crystal structure of the OX40-OX40 Ligand complex revealed that the receptor and ligand appear to interact as two trimers (Compaan and Hymowitz, 2006). Trimerization of other tumor necrosis family members has previously been shown to induce OX40 signaling (Fournel et al., 2005). Thus, trimerization of the aptamer on a tripartite scaffold may yield an even more effective agonist.

Finally, the current work is a significant advance over our previously published work with the 4-1BB aptamer with regard to clinical relevance. In the 4-1BB aptamer case, the *in vivo* activity of the aptamer complex was demonstrated following local delivery of the aptamer into a highly immunogenic, easily treatable mastocytoma-derived tumor cell line p815 (Talmage et al., 1977). In this paper, the aptamer agonist was directly injected into the tumor. By contrast, the studies described in the current paper on the OX40 receptor-activating aptamer demonstrate that an agonistic aptamer can be used to treat a highly metastatic, poorly immunogenic, and aggressive type of melanoma





**Figure 3. RNA Aptamer Dimers Are Capable of Enhancing SEB-Induced Proliferation, IFN- $\gamma$  Production, and Nuclear Translocation of NF- $\kappa$ B**

(A) Schematic of the experimental setup: murine T cells were primed in vivo by i.p. injection of SEB. After 24 hr, inguinal, axillary, and mesenteric lymph nodes were harvested. Cells were restimulated with SEB ex vivo in the absence or presence of OX40 signaling through the agonistic OX40 aptamer or agonistic antibody. Effects on cell proliferation, IFN- $\gamma$  secretion and nuclear translocation of NF- $\kappa$ B were determined.

(B) The scaffold-dimerized OX40 aptamer's effect on proliferation of SEB-primed lymph node cells was assessed by flow-cytometric analysis of the CFSE-labeled cells. An OX40 antibody agonist served as positive control. The percentage of proliferating cells is noted. The summary of three independent experiments is depicted in Figure S5).

(C) OX40 activation leads to increased IFN- $\gamma$  release. Concentrations of IFN- $\gamma$  in the culture supernatants of the previous experiment were determined by ELISA. Depicted are the mean values of three measurements. Error bars indicate  $\pm$  1 SEM; \* $p$  < 0.05.

(D) OX40 activation results in the nuclear translocation of NF- $\kappa$ B. To measure the effect of the OX40 receptor-activating aptamer on NF- $\kappa$ B localization, cells were cultured as above in the absence of CFSE labeling. After 72 hr of culture, nuclei were isolated and subjected to western blot analysis. NF- $\kappa$ B and the loading control  $\beta$ -tubulin were detected with specific antibodies and visualized by chemiluminescence.


(F10.9; Porgador et al., 1993) following systemic administration. Since most cancer patient applications will likely require systemic administration, we believe that the model employed in this study is more clinically relevant.

The large-scale synthesis of the full-length compound on a scale relevant for use as a drug would be difficult, and chemical synthesis would be low yield due to the aptamers length (80 nt). For clinical application, however, the length of the aptamer can be truncated to its functional core. The truncated aptamer can then be manufactured in large scale by chemical synthesis. Finally, we anticipate that smaller amounts of agonistic aptamers will be required to elicit phenotypic effects compared to antagonistic aptamers. Decrease in the dosage of aptamer required should lower the cost of goods.

## SIGNIFICANCE

The development of safe and effective receptor agonists have become the focus of much biomedical research. In par-

ticular, agonists that can enhance immune responses for treatment of various diseases, including cancer, are being developed and tested in preclinical and clinical studies at an ever-increasing rate. The traditional compounds used as receptor agonists have been derived from protein- and peptide-based chemistries. In this paper, we demonstrate that assembly of a nucleic acid aptamer upon an oligonucleotide scaffold can mimic the properties of these proteinaceous agents and yield a nucleic acid-based receptor agonist. Previously, it has been shown that dimerization or multimerization of receptor subunits through multivalent ligands can induce tumor necrosis factor receptor function, a receptor family that includes the receptors costimulatory receptors OX40 and CD40. We therefore generated a bivalent aptamer construct by annealing monomeric aptamers to an oligonucleotide scaffold. We included a flexible hinge in the scaffold to allow for adaptation to a span of intermolecular distances between different OX40 receptor monomers. Just as protein-based agonists, the generated receptor-activating aptamer can induce receptor function ex vivo and in vivo. Beyond merely mimicking the receptor signaling properties of protein-based agents, the agonistic aptamer has all the advantages of RNA. Due to these



(DC/TRP-2 + OX40 receptor-activating aptamer [closed squares], DC/TRP-2 + control aptamer [open squares], DC/TRP-2 + OX40 antibody [closed circles], DC/TRP-2 + isotype control [open circles]), or control antigen-transfected DCs (DC/actin + OX40 receptor-activating aptamer [closed diamonds], DC/actin + control aptamer [bold stars], DC/actin + OX40 antibody [open diamonds], DC/actin + isotype control [light stars]). The experiment was repeated three times with similar results. Enhancement in DC-TRP-2 immunotherapy is not significantly different ( $p > 0.05$ ) between OX40 Ab and OX40 receptor-activating aptamer.

inherent advantages of nucleic acid-based agonists and the generalizability of the approaches we describe, we anticipate that agonistic aptamers will emerge as a useful and safe class of therapeutic agents.

## EXPERIMENTAL PROCEDURES

### Aptamer Isolation by the SELEX Method

2' Fluoro pyrimidine RNA aptamers specific to the extracellular portion of murine OX40 were isolated by the SELEX method (Ellington and Szostak, 1990; Tuerk and Gold, 1990). An 80 nucleotide combinatorial RNA library was created by transcription of a partially randomized DNA oligonucleotide (5'-GGGGAAATTCTAATACGACTCACTATAGGGAGGACGATGCGGN40 CAGACGACTCGCTGAGGATCCGAGA3') as previously described (Layzer and Sullenger, 2007). This library was subjected to two "preclearing" steps to remove RNAs specific to human IgG Fc as well as protein G. To this end, the randomized RNA library was incubated with 1 nmol of human IgG1 (Sigma) at 37°C for 30 min. IgG-bound RNA was removed by centrifugation over a 0.4  $\mu$ m nitrocellulose Centrux column (Whatman). The preclearing step was subsequently followed by incubation with magnetic protein G-coated beads (Dyna). After bead pelleting through exposure to a magnet, the supernatant was applied to a nitrocellulose Centrux column. All binding reactions were carried out in 150 mM NaCl, 2 mM CaCl<sub>2</sub>, 20 mM HEPES (pH 7.4), 0.01% BSA buffer.

To enrich for OX40 binding RNAs, murine OX40 human IgG Fc fusion protein (R&D systems) was immobilized by coupling to protein G-coated magnetic beads (Dyna) according to manufacturer's instructions. The bead-coupled OX40 fusion protein was incubated with the precleared RNA pool and washed three times with a 20-fold excess volume wash buffer (150 mM NaCl, 2 mM CaCl<sub>2</sub>, 20 mM HEPES [pH 7.4]) to remove noninteracting RNA. RNA bound to OX40 was extracted by a 30 min incubation in phenol:chloroform:isoamyl alcohol (25:24:1). The RNA was amplified by reverse transcription followed by PCR.

A secondary, enriched RNA pool was created by transcription with a 2'OH purine, 2'F pyrimidine nucleotide mixture with T7 polymerase. Transcripts were gel purified and eluted into TE, pH 7.5 (10 mM Tris [pH 7.5], 0.1 mM EDTA). Following overnight elution, RNA was washed three times in TE (pH 7.5) with Centricon 30 columns (Millipore).

Eleven rounds of selection were performed with increasing stringency throughout the selection process by increasing the RNA:protein ratio in the selection reaction. Aptamers from rounds 9 and 11 DNA were cloned into the EcoRI/BamHI (New England Biolabs) sites in a pUC18 plasmid. Single colonies were sequenced and amplified by low-cycle PCR amplification followed by in vitro transcription.

### Monomeric Aptamer Binding Affinity

Binding constants were determined with filter binding assays in buffer composed of 20 mM HEPES (pH 7.4), 150 mM NaCl, and 2 mM CaCl<sub>2</sub>. To determine the affinities of monomeric aptamers, serial dilutions of murine OX40 IgG Fc fusion protein (R&D systems), human IgG1 (Sigma), or protein G (Zymed) were incubated with monomeric 5' <sup>32</sup>P-radiolabeled aptamers at 2000 cpm/ $\mu$ l. The mixture was passed over a stack of membranes consisting of a Protran nitrocellulose and GeneScreen Plus nylon membrane through application of a vacuum. The membranes were exposed to a phosphorimager screen, scanned, and quantitated with a Molecular Dynamics Storm 840 phosphorimager. Finally, differential fractions of RNA bound were calculated and graphed with Prism (Layzer and Sullenger, 2007).

### Aptamer Structure Prediction

The predicted secondary structure of generated aptamers was determined by utilizing the algorithm m-fold (<http://bioweb.pasteur.fr/seqanal/interfaces/mfold.html>) with default settings for folding parameters.

### Generation of Point Mutant Aptamer

The point mutant RNA aptamer was generated by in vitro transcription of DNA template produced by annealing two oligonucleotides. One nanomole of each oligonucleotide (5'-GGGGAAATTCTAATACGACTCACTATAGGGAGGACGATGCGGCAGTCTGCATCGTAGGATAGC-3' and 5'-TCTCGGATCCTCAGCGAGTCTGCTGGTGGGAAAGTATACGGTGCGCTAATCCTACGATGCAGACTG-3') was heated to 95°C for 5 min and annealed by cooling to 4°C. A double-stranded DNA transcription template was created by treatment with Exo-Klenow fragment (New England Biolabs). The reaction was stopped by the addition of 2 mM EDTA followed by phenol:chloroform and chloroform extraction. The template was purified by triplicate washing with a Centricon 30 column and 10 mM Tris (pH 7.5), 0.1 mM EDTA buffer. 2'F modified point mutant RNA aptamer was generated through in vitro transcription with T7 polymerase.

### Aptamer Dimerization

A DNA scaffold consisting of a 20 nucleotide repeat of the complementary sequence of 3' fixed region of the aptamer separated by an 18 carbon spacer (Operon) (5'-TCTCGGATCCTCAGCGAGT carbon spacer TCTCGGATCCTCAGCGAGT-3') was used to dimerize RNA aptamers. RNA aptamers were mixed with this scaffold at a 2:1 molar ratio of RNA to scaffold. The mixture was heated to 95°C for 5 min, followed by slow cooling to room temperature.

For binding affinity determination, aptamer dimers were purified with 8% native PAGE purification, followed by overnight elution into 2 ml of TE (pH 7.5) buffer at 4°C, followed by extensive washing, as described above.

### Quantification of Dimer Aptamer Binding Affinity

Radioactive labeling of monomeric RNA normally involves a dephosphorylation step at 65°C with bacterial alkaline phosphatase (Invitrogen), followed by

radioactive labeling with T4 kinase and  $^{32}\text{P}$   $\gamma$ -labeled ATP. However, gel-purified RNA dimers are heat labile and, therefore, could not be heated to  $65^\circ\text{C}$ . Therefore, dimers were  $3'$  radiolabeled by incubation with T4 RNA ligase (Ambion) according to the manufacturer's instructions at  $4^\circ\text{C}$ . This method leads to a lower incorporation efficiency, but has the advantage of avoiding exposure of the dimer to heat. Binding affinities were determined as described for the aptamer monomer.

#### Proliferation Assay

Activation of OX40 leads to increased T cell proliferation. We therefore tested the effect of the dimerized aptamers on activation of OX40 and the consequent increase in lymph node cell proliferation (Ali et al., 2004). A total of  $50\text{ }\mu\text{g}$  SEB (Sigma) resuspended in phosphate-buffered saline (PBS; GIBCO, Grand Island, NY) was administered to female Balb/c mice intraperitoneally. Auxiliary, inguinal, and mesenteric lymph nodes were harvested after 24 hr. Cells were teased into single cell suspension and labeled with CFSE (Pierce) by incubating cells at a concentration of  $10^6$  cells/ml in PBS containing 5% fetal bovine serum (FBS; HyClone) and 2 mM CFSE at room temperature for 5 min. Cells were washed twice with PBS with 5% FBS, followed by a final wash with RPMI containing 10% FBS.

A total of  $10^5$  cells were seeded in wells of a round bottom 96-well plate (Corning) and were cultured for 72 hr in complete RPMI (GIBCO) containing 10% FBS, in the presence of 0.5 ng/ml SEB in a humidified chamber at  $37^\circ\text{C}/5\%\text{ CO}_2$ . Experimental groups also included 33 nM OX40 agonistic antibody (OX86), isotype control (ebiosciences), 66 nM of aptamer dimer or point mutant aptamer dimer. Groups were set up in five replicates and pooled for analysis. Cell proliferation data were collected by flow cytometry with a FACS-calibur and evaluated with CellQuest software (Becton Dickinson).

#### Determination of IFN- $\gamma$ Concentration in Tissue Culture Supernatants

Supernatants of proliferation assay replicates were pooled after 72 hr of culture. IFN- $\gamma$  secretion was measured in triplicate with the Ready Set Go Elisa kit (ebiosciences) following the manufacturer's instructions.

#### Nuclear NF- $\kappa\text{B}$ Detection

NF- $\kappa\text{B}$  is translocated to the nucleus as a result of OX40 signaling. As a measure of OX40 activation, we therefore determined presence of nuclear NF- $\kappa\text{B}$  in murine lymph node cells incubated with the aptamer or point mutant dimer compared to the agonistic OX40 antibody. Mice were injected with SEB and lymph nodes harvested as described in the proliferation assay. Cells were teased into single cell suspension and  $10^5$  cells per 96-well plate were seeded in complete RPMI containing 0.5 ng/ml SEB. Aptamer dimers or antibodies were added at a concentration of 66 nM. After 72 hr culturing, cells were pelleted and nuclei were isolated with the Sigma CellLytic NuCLEAR Extraction kit according to manufacturer's instructions for hypotonic nuclear isolation (Mi et al., 2006). The absorbance of the generated protein fractions at A280 was determined. Equivalent amounts of protein were loaded onto a 4%–15% denaturing PAGE gel (Biorad) and transferred to a polyvinylidene difluoride membrane by electroblotting. NF- $\kappa\text{B}$  was detected with a specific primary antibody (Santa Cruz Biotechnology) followed by incubation with a horseradish peroxidase-labeled secondary antibody (goat anti-rabbit; Santa Cruz Biotechnology). Protein was visualized with the ECL plus chemiluminescence detection kit (GE Amersham) and captured through exposure to film. Antibodies were removed from the membranes by a 15 min incubation with Restore Western Blotting Stripping Buffer (Pierce). Successful stripping was verified by treatment with chemiluminescence reagents and exposure to film. The nuclear protein loading control  $\beta$ -tubulin was detected through incubation with a primary followed by a secondary HRP-conjugated antibody.

#### Murine Bone Marrow Precursor-Derived DC

Marrow from tibias and femurs of C57BL/6 mice were harvested followed by treatment of the precursors with ammonium chloride Tris buffer for 3 min at  $37^\circ\text{C}$  to deplete the red blood cells. The precursors were plated in RPMI with 5% FCS and GM-CSF (15 ng/ml) and IL-4 (10 ng/ml). GM-CSF and IL-4 were obtained from Protech (Rocky Hill, NJ). Cells were plated at  $10^6$ /ml and incubated at  $37^\circ\text{C}$  and 5%  $\text{CO}_2$ . Three days later, the floating cells (mostly granulocytes) were removed and the adherent cells replenished with fresh

GM-CSF and IL-4 containing medium. Four days later, the nonadherent cells were harvested, washed, and electroporated with RNA.

#### Electroporating Murine DC with RNA

DC were harvested on Day 7, washed, and gently resuspended in Opti-MEM (GIBCO) at  $2.5 \times 10^7$ /ml. The used DC culture media was saved as conditioned media for later use. Cells were electroporated in 2 mm cuvettes (200  $\mu\text{l}$  of DC [ $5 \times 10^6$  cells] at 300 V for 500  $\mu\text{s}$  using an Electro Square Porator ECM 830 [BTX, San Diego, CA]). The amount of TRP-2 or actin RNA used was 3  $\mu\text{g}/10^6$  DC. Cells were immediately transferred to six well plates containing a 1:1 combination of conditioned DC growth medium and fresh RPMI with GMCSF and IL-4. Transfected cells were incubated at  $37^\circ\text{C}$ , 5%  $\text{CO}_2$  for 4 hr in the presence of 100 ng/ml LPS (L265L, *E. coli* 026:B6; Sigma), washed twice in PBS, and then injected into mice.

#### Statistical Analysis

Statistical analysis was performed with the graphing software Prism. Two-tailed, nonparametric t tests were carried out with the default parameters. Statistical analysis of in vivo data was completed with the logrank (Mantel-Haenszel test). Confidence intervals equal to or less than 0.05 were considered to constitute statistical significance.

#### SUPPLEMENTAL DATA

Supplemental Data include seven figures and are available online at <http://www.chembiol.com/cgi/content/full/15/7/675/DC1/>.

#### ACKNOWLEDGMENTS

This publication was made possible by grant 1UL1 RR024128-01 from the National Institutes for Research Resources, a component of the National Institutes of Health (NIH), and roadmap for Medical Research to S.N., as well as grant HL065222 from the NIH to B.A.S. We would like to thank D. Snyder, J. Mi, and Y. Liu for their technical assistance, and D.E. Dollins as well as M. Kierlin-Duncan for critical reading of this manuscript. Thanks to B. Ramsay Shaw for critical discussions. B.A.S. and E.G. are scientific founders of Argos Biosciences, a company focused on the clinical development of DC-based vaccines, and B.A.S. is a scientific founder of b3 Bio Inc., a biotechnology company focused upon using aptamers as delivery agents. Neither company provided any support for the studies performed in the manuscript.

Received: February 25, 2008

Revised: May 16, 2008

Accepted: May 28, 2008

Published: July 18, 2008

#### REFERENCES

- Aggarwal, B.B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. *Nat. Rev. Immunol.* 3, 745–756.
- Ali, S.A., Ahmad, M., Lynam, J., McLean, C.S., Entwistle, C., Loudon, P., Choolun, E., McArdle, S.E., Li, G., Mian, S., et al. (2004). Anti-tumour therapeutic efficacy of OX40L in murine tumour model. *Vaccine* 22, 3585–3594.
- al-Shamkhani, A., Birkeland, M.L., Puklavec, M., Brown, M.H., James, W., and Barclay, A.N. (1996). OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. *Eur. J. Immunol.* 26, 1695–1699.
- Arch, R.H., and Thompson, C.B. (1998). 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. *Mol. Cell. Biol.* 18, 558–565.
- Burmeister, P.E., Lewis, S.D., Silva, R.F., Preiss, J.R., Horwitz, L.R., Pendergrast, P.S., McCauley, T.G., Kurz, J.C., Epstein, D.M., Wilson, C., et al. (2005). Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. *Chem. Biol.* 12, 25–33.
- Compaan, D.M., and Hymowitz, S.G. (2006). The crystal structure of the costimulatory OX40-OX40L complex. *Structure* 14, 1321–1330.

- Dyke, C.K., Steinhilbl, S.R., Kleiman, N.S., Cannon, R.O., Aberle, L.G., Lin, M., Myles, S.K., Melloni, C., Harrington, R.A., Alexander, J.H., et al. (2006). First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. *Circulation* 114, 2490–2497.
- Ellington, A.D., and Szostak, J.W. (1990). In vitro selection of RNA molecules that bind specific ligands. *Nature* 346, 818–822.
- Fitzwater, T., and Polisky, B. (1996). A SELEX primer. *Methods Enzymol.* 267, 275–301.
- Fournel, S., Wieckowski, S., Sun, W., Trouche, N., Dumortier, H., Bianco, A., Chaloin, O., Habib, M., Peter, J.C., Schneider, P., et al. (2005). C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. *Nat. Chem. Biol.* 1, 377–382.
- Kawamata, S., Hori, T., Imura, A., Takaori-Kondo, A., and Uchiyama, T. (1998). Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF- $\kappa$ B activation. *J. Biol. Chem.* 273, 5808–5814.
- Kleinman, M.E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J.Z., Albuquerque, R.J., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. *Nature* 452, 591–597.
- Layzer, J.M., and Sullenger, B.A. (2007). Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. *Oligonucleotides* 17, 1–11.
- Macugen AMD Study Group/Apte, R.S., Modi, M., Masonson, H., Patel, M., Whitfield, L., and Adamis, A.P. (2007). Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology* 114, 1702–1712.
- McNamara, J.O., Kolonias, D., Pastor, F., Mittler, R.S., Chen, L., Giangrande, P.H., Sullenger, B., and Gilboa, E. (2007). Multivalent 4-1BB binding aptamers costimulate CD8 T cells and inhibit tumor growth in mice. *J. Clin. Invest.* 118, 376–386.
- Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M., and Chen, L. (2007). Immunostimulatory monoclonal antibodies for cancer therapy. *Nat. Rev. Cancer* 7, 95–106.
- Mi, J., Zhang, X., Rabbani, Z.N., Liu, Y., Su, Z., Vujaskovic, Z., Kontos, C.D., Sullenger, B.A., and Clary, B.M. (2006). H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. *Nucleic Acids Res.* 34, 3577–3584.
- Morris, N.P., Peters, C., Montler, R., Hu, H.M., Curti, B.D., Urba, W.J., and Weinberg, A.D. (2007). Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. *Mol. Immunol.* 44, 3112–3121.
- Nair, S., and Boczkowski, D. (2002). RNA-transfected dendritic cells. *Expert Rev. Vaccines* 1, 507–513.
- Nair, S., Boczkowski, D., Fassnacht, M., Pisetsky, D., and Gilboa, E. (2007). Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. *Cancer Res.* 67, 371–380.
- Nimjee, S.M., Rusconi, C.P., and Sullenger, B.A. (2005). Aptamers: an emerging class of therapeutics. *Annu. Rev. Med.* 56, 555–583.
- Nimjee, S.M., Keys, J.R., Pitoc, G.A., Quick, G., Rusconi, C.P., and Sullenger, B.A. (2006). A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. *Mol. Ther.* 14, 408–415.
- Porgador, A., Gansbacher, B., Bannerji, R., Tzeheval, E., Gilboa, E., Feldman, M., and Eisenbach, L. (1993). Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. *Int. J. Cancer* 53, 471–477.
- Rusconi, C.P., Scardino, E., Layzer, J., Pitoc, G.A., Ortel, T.L., Monroe, D., and Sullenger, B.A. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. *Nature* 419, 90–94.
- Santulli-Marotto, S., Nair, S.K., Rusconi, C., Sullenger, B., and Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. *Cancer Res.* 63, 7483–7489.
- Sugamura, K., Ishii, N., and Weinberg, A.D. (2004). Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. *Nat. Rev. Immunol.* 4, 420–431.
- Talmage, D.W., Woolnough, J.A., Hemmingsen, H., Lopez, L., and Lafferty, K.J. (1977). Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s). *Proc. Natl. Acad. Sci. USA* 74, 4610–4614.
- Tuerk, C., and Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science* 249, 505–510.
- Watts, T.H. (2005). TNF/TNFR family members in costimulation of T cell responses. *Annu. Rev. Immunol.* 23, 23–68.
- Weinberg, A.D. (2002). OX40: targeted immunotherapy—implications for tempering autoimmunity and enhancing vaccines. *Trends Immunol.* 23, 102–109.
- Weinberg, A.D., Thalhofer, C., Morris, N., Walker, J.M., Seiss, D., Wong, S., Axthelm, M.K., Picker, L.J., and Urba, W.J. (2006). Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. *J. Immunother.* 29, 575–585.
- Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.* 31, 3406–3415.